Barclays’s Compass Therapeutics CMPX Stock Holding History

Barclays’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1M	Buy	+207,100	New	+$1.2M	﹤0.01%	2704

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's CMPX Position: Q1 2026 in Review

Barclays increased its Compass Therapeutics (CMPX) stake by 33% in Q1 2026, buying an estimated $1.13M and bringing the position to 790,041 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

Barclays first reported a position in CMPX in Q3 2022 and has held it in 15 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

Barclays held 790,041 shares of Compass Therapeutics worth $4.18M as of Q1 2026.
Barclays bought 195,265 Compass Therapeutics shares in Q1 2026, an estimated $1.13M.
Compass Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1929 holding.
Barclays first reported a position in Compass Therapeutics in Q3 2022 and has held it in 15 quarters since.
201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.